Credit: Alvogen, Inc. Fentanyl is an opioid agonist indicated for the management of severe or persistent pain in opioid-tolerant patients. At this time, Alvogen Inc has received 1 serious adverse ...

Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance. Nutriband ...

Morristown-based Alvogen Inc. announced two lots of a transdermal patch used for delivery of the synthetic opioid Fentanyl have been recalled because the patches inside some cartons may contain a ...

Objective: To summarize the pharmaceutics, pharmacokinetics, development, and clinical application of IONSYS, the fentanyl HCl patient-controlled iontophoretic transdermal system for the management of ...

Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the recall is that there is a potential that patches ...

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function The transdermal GFR (tGFR) methodology has ...

A transdermal amphetamine therapy was effective at treating pediatric ADHD, according to a phase II trial. In a two-part study, children with attention deficit-hyperactivity disorder (ADHD) using the ...

Please provide your email address to receive an email when new articles are posted on . MediBeacon Inc. announced it received a breakthrough device designation from the FDA for the company’s ...

VANCOUVER, BC / ACCESSWIRE / June 8, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, ...

Philadelphia, US – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its methylphenidate transdermal system (MTS), DAYTRANA TM demonstrated statistically significant reductions in the ...

Obtaining the EU CE Mark is a significant milestone for MediBeacon,” said Steven Hanley, CEO and Co-Founder of MediBeacon. “As the TGFR ™ System enters the clinic in the U.S. and China, the CE Mark ...

The US Food and Drug Administration (FDA) has approved donepezil transdermal system (Adlarity) for patients with mild, moderate, or severe Alzheimer's disease (AD), the manufacturer has announced.